Related Experiment Video
Updated: Jun 26, 2026

SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs
Published on: June 28, 2019
Hallmarks for senescence in carcinogenesis: novel signaling players
M Cecilia Caino1, John Meshki, Marcelo G Kazanietz
1Department of Pharmacology, School of Medicine, University of Pennsylvania, Philadelphia, PA 19104-6160, USA.
Abstract:
Cellular senescence is a potent anti-cancer mechanism controlled by tumor suppressor genes, particularly p53 and pRb, which is characterized by the irreversible loss of proliferation. Senescence induced by DNA damage, oncogenic stimulation, or excessive mitogenic input, serves as a barrier that counteracts cancer progression. Emerging evidence in cellular and in in vivo models revealed the involvement of additional signaling players in senescence, including PML, CK2, Bcl-2, PI3K effectors such as Rheb, Rho small GTPases, and cytokines. Recent studies have also implicated protein kinase C (PKC) isozymes as modulators of senescence phenotypes and showed that phorbol esters, widely used PKC activators, can induce senescence in a number of cancer cells. These novel findings suggest a complex array of cross-talks between senescence pathways and may have significant implications in cancer therapy.
Insights
Cellular senescence, a tumor suppressor mechanism, halts cancer cell proliferation. Novel research reveals protein kinase C (PKC) activation can induce senescence, offering new therapeutic strategies against cancer.
Area of Science:
- Oncology
- Cell Biology
- Molecular Biology
Background:
- Cellular senescence is a critical anti-cancer mechanism.
- Tumor suppressor genes like p53 and pRb control senescence, preventing cancer progression.
- Senescence is triggered by DNA damage, oncogenic signals, or excessive mitogenic input.
Purpose of the Study:
- To explore novel signaling pathways involved in cellular senescence.
- To investigate the role of protein kinase C (PKC) isozymes in modulating senescence phenotypes.
- To assess the potential of PKC activators in cancer therapy.
Main Methods:
- Review of emerging evidence in cellular and in vivo models.
- Analysis of signaling players including PML, CK2, Bcl-2, PI3K effectors, Rho small GTPases, and cytokines.
- Examination of phorbol ester-induced senescence in cancer cells.
Main Results:
- Identified diverse signaling molecules contributing to senescence.
- Demonstrated that phorbol esters, PKC activators, can induce senescence in various cancer cells.
- Highlighted the complex interplay between senescence pathways.
Conclusions:
- Cellular senescence is a multifaceted process involving numerous signaling pathways.
- PKC isozymes are significant modulators of senescence.
- Targeting senescence pathways, particularly via PKC activation, holds promise for novel cancer therapies.
Related Concept Videos
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not until 1985...
Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not until 1985...
Role Of Notch Signalling In Intestinal Stem Cell Renewal
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
